What is the recommended insulin therapy regimen for a pregnant woman with pregestational diabetes?

Insulin Therapy for Pregestational Diabetes in Pregnancy

For pregnant women with pregestational diabetes, use multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) with rapid-acting insulin analogs (lispro or aspart) for prandial coverage and NPH, detemir, or glargine for basal insulin. 1

Insulin Regimen Structure

The preferred approach is basal-bolus therapy rather than premixed insulin formulations, as this provides the flexibility needed for frequent dose adjustments throughout pregnancy 2. This typically involves:

• Rapid-acting insulin analogs (lispro or aspart) before meals for postprandial control
• Basal insulin to cover overnight and between-meal periods

Rapid-Acting Insulin (Prandial Coverage)

Use insulin lispro or aspart in preference to regular insulin 3, 2. These rapid-acting analogs:

• Better control postprandial hyperglycemia
• Reduce hypoglycemia risk compared to regular insulin
• Have established safety data in pregnancy 2, 4

Basal Insulin Options

For basal coverage, you have three evidence-based options 2:

1. NPH insulin - Traditional choice, lower cost
2. Insulin detemir - May be initiated during pregnancy; preferred if NPH causes problematic hypoglycemia 2
3. Insulin glargine - Can be continued if successfully used preconceptionally 2

Important caveat: While insulin detemir is FDA-approved for pregnancy, glargine is not, though it's widely used with evidence of safety 2. Detemir and glargine both reduce nocturnal hypoglycemia compared to NPH 2.

Delivery Method: MDI vs. Insulin Pump

Both multiple daily injections and continuous subcutaneous insulin infusion are reasonable strategies - neither has proven superior 1. However:

• Continue CSII if already established preconceptionally 2
• Do not initiate pump therapy during pregnancy unless MDI has failed 2
• For type 1 diabetes in pregnancy, hybrid closed-loop pumps are preferred over standard pumps with CGM 5

The 2023 ADA guidelines note that predictive low-glucose suspend technology reduces hypoglycemia better than sensor-augmented pumps alone 1.

Glycemic Targets During Pregnancy

Monitor preprandial and postprandial glucose to guide insulin adjustments 4. Target values are 2, 4:

• Fasting/preprandial: 70-95 mg/dL (3.9-5.3 mmol/L)
• 1-hour postprandial: 110-140 mg/dL (6.1-7.8 mmol/L)
• 2-hour postprandial: 100-120 mg/dL (5.6-6.7 mmol/L)
• A1C: <6% if achievable without significant hypoglycemia 4

Insulin Dose Adjustments Throughout Pregnancy

Insulin requirements change dramatically across trimesters 4, 6:

• First trimester: Enhanced insulin sensitivity; expect lower insulin needs and increased hypoglycemia risk 4
• Second/third trimester: Insulin resistance increases ~5% per week through week 36, typically doubling total daily dose from prepregnancy 4
• Postpartum: Insulin requirements drop dramatically immediately after placental delivery 1

This physiologic pattern necessitates frequent titration - often weekly or biweekly adjustments in the second and third trimesters 7, 6.

Critical Preconception Considerations

Optimize insulin regimen well before conception 2:

• Switch to MDI or CSII at least 3 months before attempting pregnancy
• Transition to rapid-acting analogs (lispro/aspart) preconceptionally
• Women successfully using detemir or glargine may continue these through pregnancy 2

Common Pitfalls to Avoid

1. Using premixed insulin - Lacks flexibility for pregnancy's changing insulin needs 2
2. Inadequate dose escalation - Failing to increase insulin aggressively in second/third trimester leads to hyperglycemia
3. Continuing prepregnancy insulin doses postpartum - Risk of severe hypoglycemia 1
4. Relying solely on A1C - Use as secondary measure; postprandial monitoring is essential 4, 7

Role of Non-Insulin Agents

Insulin is the preferred and only FDA-approved medication for pregestational diabetes in pregnancy 1, 8. The 2023 ADA guidelines specifically recommend against routinely adding metformin to insulin in type 2 diabetes due to increased risk of small-for-gestational-age infants 1, 5.

Team-Based Care

Given the complexity of insulin management requiring frequent adjustments, referral to a specialized center with multidisciplinary team care is strongly recommended when available 1. This should include maternal-fetal medicine, endocrinology, diabetes educators, and dietitians 1.